|Bid||20.58 x 800|
|Ask||20.62 x 1000|
|Day's Range||20.28 - 21.31|
|52 Week Range||16.21 - 37.88|
|Beta (5Y Monthly)||1.55|
|PE Ratio (TTM)||51.10|
|Earnings Date||Mar 21, 2023 - Mar 27, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||46.75|
- 2023 will produce significant advances for both anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and adenosine A2A receptor antagonist inupadenant - Eleven clinical trials planned or ongoing against multiple tumor types, across three pipeline programs - EOS-984, a first-in-class program targeting a new mechanism of action in the adenosine pathway, expected to enter clinical studies mid-2023 - Cash balance of $752MM as of September 30, 2022, expected to provide runway into 2026 through multip
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 03, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Conference being held in San Francisco, CA on Tuesday, January 10, 2023 at 8:15 a.m. PST (11:15 a.m. EST).
iTeos Therapeutics (NASDAQ:ITOS) has had a rough three months with its share price down 8.4%. But if you pay close...